Actinium Pharmaceuticals
web2Actinium Pharmaceuticals develops targeted radiotherapies designed to deliver radiation to canc...
About
Actinium Pharmaceuticals develops targeted radiotherapies designed to deliver radiation to cancer cells, with research and clinical programs focused on difficult-to-treat malignancies including relapsed cancers. Its pipeline includes Actimab-A for acute myeloid leukemia, ATNM-400, a HER3-targeted radiotherapy candidate for prostate cancer, and Iomab-ACT, a conditioning candidate being studied for cell and gene therapies. The pipeline also includes Iomab-B, intended for use before bone-marrow transplantation in patients with relapsed or refractory acute myeloid leukemia, and the company has sought a potential US partner for that program. Its operating focus is research, discovery, and clinical development rather than marketing an established portfolio of medicines.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
Actinium Pharmaceuticals profile.
Expert coverage
No published expert evaluations are available for this project yet.
Orbitrum Academy